Biomedical subjects

Corinne Dagada

Publications and source records attributed to Corinne Dagada.

2 recordsLinked to original sources

PubMed2003

[Management of cancer patients by general practitioners. Results of a survey among 422 physicians in Aquitaine].

OBJECTIVE: To have a better knowledge on the role of the general practitioner in the management of cancer patients, their opinion on communications with the specialists and their training in oncology. METHOD: In March 2000, a questionnaire was sent to a random sample of 730 general practitioners in the Aquitaine area. RESULTS: We obtained 440 answers (60%). The general practitioners declared taking care of a mean of 16 cancer patients among their clientele and seeing 5 new cases every year. Two thirds of them decided on the orientation of their patients, case by case. Nearly 70% of the practitioners reported difficulties, notably psychological, in the case of relapses or during the terminal phase. The majority (94%) considered the quality of the information provided by the specialists as correct or good. Globally, the practitioners would prefer to be more involved in the treatment of their cancer patients and 82% would accept to ensure the follow-up of the patients in remission. CONCLUSION: The expectations of the general practitioners defined in this study merit reflection for the development of treatment networks in order to improve their organisation and the collaboration between general practitioners and specialists.

Adult↗

PubMed2002

[Update on soft tissue sarcomas].

Important refinements have taken place in the diagnosis of soft tissue sarcoma with extensive use of immuno-histochemistry. New entities have been described, while malignant histiocytofibroma, the most diagnosed sarcoma type during the last two decades, has been dismembered. As for prognosis, the new UICC classification is effectively more discriminating in the definition of prognostic groups; but the usefullness of new biological or genetic markers remains to be assessed. Several breakthrough have taken place in the last years in the treatment of soft tissue sarcoma. Isolated limb perfusion with TNF, hyperthermia and melphalan have proven its efficacy, and is now an alternative to preoperative chemotherapy and/or radiotherapy for limb sparing treatment of the primary tumor site or to amputation. For systemic treatments, novel cytostatic drugs have been shown to be active in sarcomas, including ecteinascidine (ET743) and Glivec (STI571). This last drug has been shown to be remarkably active in c-kit+ stromal sarcoma of the gastro-intestinal tract. It can hopefully regarded as an example for targeted therapies, which may come with a better understanding of the molecular mechanisms triggered by the fundamental, specific genetic alterations shown in sarcoma.

Chemotherapy, Adjuvant↗